LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch LIXT
See up to 3 months of LIXT. The 7-day demo opens the 1M and 3M ranges and puts LIXT on your watchlist.
Start 7-day demoLatest LIXT insider trades
About LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. files with the SEC under CIK 0001335105 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
LIXT Form 4 activity by transaction type, last 90 days
No Form 4 activity for LIXT in the last 90 days.
LIXT insider transactions (Form 4)
3727 Form 4 filings on record, the earliest from Oct 29, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Peter Stazzone - Officer | Grant or award | Common Stock | 50,000 footnote F1 | $0.00 | - | |
| ||||||
| Jason David Sawyer - Director | Grant or award | Common Stock | 40,000 footnote F1 | $0.00 | - | |
| ||||||
| Geordan Garrett Pursglove - Officer | Grant or award | Common Stock | 350,000 footnote F1 | $0.00 | - | |
| ||||||
| Guy Warren Primus - Director | Grant or award | Common Stock | 15,000 footnote F1 | $0.00 | - | |
| ||||||
| Michael Andrew Holloway - Director | Grant or award | Common Stock | 15,000 footnote F1 | $0.00 | - | |
| ||||||
| Lourdes Felix - Director | Grant or award | Common Stock | 30,000 footnote F1 | $0.00 | - | |
| ||||||
| Stuart D. Porter - Director | Grant or award | Common Stock | 25,000 footnote F1 | $0.00 | - | |
| ||||||
| Geordan Garrett Pursglove - Officer | Grant or award | Common Stock | 350,000 | - footnote F1 | - | |
| Geordan Garrett Pursglove - Officer | Derivative | Options to Purchase Common Stock | 350,000 | - footnote F1 | - | |
| ||||||
| Peter Stazzone - Officer | Grant or award | Common Stock | 50,000 | - footnote F1 | - | |
| Peter Stazzone - Officer | Derivative | Options to Purchase Common Stock | 50,000 | - footnote F1 | - | |
| ||||||
| Lourdes Felix - Director | Grant or award | Common Stock | 25,000 | - footnote F1 | - | |
| Lourdes Felix - Director | Derivative | Stock Option (right to buy) | 25,000 | - footnote F1 | - | |
| ||||||
| Jason David Sawyer - Director | Grant or award | Common Stock | 25,000 | - footnote F1 | - | |
| Jason David Sawyer - Director | Derivative | Options to Purchase Common Stock | 25,000 | - footnote F1 | - | |
| ||||||
| Michael Andrew Holloway - Director | Grant or award | Common Stock | 25,000 | - footnote F1 | - | |
| Michael Andrew Holloway - Director | Derivative | Options to Purchase Common Stock | 25,000 | - footnote F1 | - | |
| ||||||
| Guy Warren Primus - Director | Grant or award | Common Stock | 25,000 | - footnote F1 | - | |
| Guy Warren Primus - Director | Derivative | Stock Option (right to buy) | 25,000 | - footnote F1 | - | |
| ||||||
| Guy Warren Primus - Director | Grant or award | Stock Option (right to buy) | 25,000 | $0.00 | - | |
| Lourdes Felix - Director | Grant or award | Stock Option (right to buy) | 25,000 | $0.00 | - | |
| Peter Stazzone - Officer | Grant or award | Options to Purchase Common Stock | 50,000 | $0.00 | - | |
| Jason David Sawyer - Director | Grant or award | Options to Purchase Common Stock | 25,000 | $0.00 | - | |
| Michael Andrew Holloway - Director | Grant or award | Options to Purchase Common Stock | 25,000 | $0.00 | - | |
| Geordan Garrett Pursglove - Officer | Grant or award | Options to Purchase Common Stock | 350,000 | $0.00 | - | |
| Yun Yen - Director | Grant or award | Options to Purchase Common Stock | 10,000 | $0.00 | - | |
| Yun Yen - Director | Grant or award | Options to Purchase Common Stock | 11,632 | $0.00 | - | |
| Stephen J. Forman - Director | Grant or award | Options to Purchase Common Stock | 10,000 | $0.00 | - | |
| Stephen J. Forman - Director | Grant or award | Options to Purchase Common Stock | 7,754 | $0.00 | - | |
| Rene Bernards - Director | Grant or award | Options to Purchase Common Stock | 10,000 | $0.00 | - | |
| Rene Bernards - Director | Grant or award | Options to Purchase Common Stock | 10,662 | $0.00 | - | |
| Regina Brown - Director | Grant or award | Options to Purchase Common Stock | 10,000 | $0.00 | - | |
| Regina Brown - Director | Grant or award | Options to Purchase Common Stock | 12,600 | $0.00 | - | |
| Yun Yen - Director | Grant or award | Options to Purchase Common Stock | 5,786 | $0.00 | - | |
| Stephen J. Forman - Director | Grant or award | Options to Purchase Common Stock | 3,858 | $0.00 | - | |
| Rene Bernards - Director | Grant or award | Options to Purchase Common Stock | 5,304 | $0.00 | - | |
| Regina Brown - Director | Grant or award | Options to Purchase Common Stock | 6,269 | $0.00 | - | |
Item 7.01, 9.01
Item 1.01, 3.02, 9.01
Item 9.01
Item 7.01, 9.01
LIXT insider trading FAQ
What is the latest insider trade for LIXT?
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-07-02. The full record for LIXT runs to 27 Form 4 filings, the earliest from 2024-10-29. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying LIXT stock?
No insider purchases of LIXT were filed in the last 90 days.
How many insiders are selling LIXT stock?
No insider sales of LIXT were filed in the last 90 days.
Where can I see LIXT SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects LIXT Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Peter Stazzone view on EDGAR
- - Jason David Sawyer view on EDGAR
- - Geordan Garrett Pursglove view on EDGAR
- - Guy Warren Primus view on EDGAR
- - Michael Andrew Holloway view on EDGAR
- - Lourdes Felix view on EDGAR
- - Stuart D. Porter view on EDGAR
- - Geordan Garrett Pursglove view on EDGAR
- - Peter Stazzone view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where LIXT's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow LIXT with a 7-day demo
- LIXT on your watchlist
- Every LIXT Form 4 filing on record
- Up to 3 months of LIXT price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
